#United States #Overland Park #Parnell #PropofolVet #Veterinary Anesthesia

Parnell's New Solution for Canine Anesthesia

Parnell, a prominent name in pet care product manufacturing, has recently unveiled PropofolVet Multidose, marking a significant advancement in veterinary medicine. This newly introduced injectable anesthetic emulsion is tailored specifically for dogs, enabling veterinarians to streamline their anesthesia protocols while ensuring top-notch patient care. With its versatile applications, PropofolVet Multidose promises to enhance the efficiency and flexibility of veterinary practices.

Understanding PropofolVet Multidose

PropofolVet Multidose is designed to aid veterinary professionals during anesthesia induction and maintenance. This product allows for intermittent bolus injections, particularly beneficial for short surgical procedures. Additionally, it can facilitate anesthesia induction when combined with inhalant anesthetics during longer operations. Chelsie Estey, DVM, and Vice President of U.S. Pet Care at Parnell, articulates the objectives of this development, stating, "We recognize the multifaceted challenges veterinarians encounter in anesthesia protocols. PropofolVet Multidose represents a crucial enhancement to our anesthesia portfolio. Our goal is to empower veterinary teams with not only access to high-quality products but also the confidence to utilize them effectively."

Key Features of PropofolVet Multidose

• - Quality and Affordability: Positioned as a cost-effective alternative to PropoFlo™ 28, PropofolVet does not compromise on quality.
• - First Generic Offering: It stands out as the first generic propofol injectable emulsion designed specifically for dogs.
• - Extended Shelf Life: With a 28-day in-use shelf life, the product eliminates the need for refrigeration, simplifying storage concerns.
• - Consistent Results: Veterinary practices can rely on this product for consistent and high-quality anesthesia induction, ensuring patient safety throughout the surgical process.

Meeting Market Demand

Speaking on the importance of this launch, Pablo Lamberto, DVM and Senior Vice President of U.S. Operations for Parnell, highlighted the critical market gap that PropofolVet Multidose fills. He stated, "As the first generic proposition in the field of veterinary anesthesia, this product addresses a pivotal need in the market. It equips veterinarians with an effective, affordable solution that ultimately drives operational efficiency without compromising on care standards."

Comprehensive Anesthesia Portfolio

Parnell’s new offering will enhance their existing range of anesthesia and sedation solutions, which includes Dexmedetomidine Hydrochloride Injection and CONTRASED™ (atipamezole hydrochloride). By refining inventory management and providing a complete sedation and anesthesia solution, Parnell is positioned to support veterinary practices with a comprehensive suite of products.

Conclusion

Veterinary professionals are encouraged to reach out to their distributor representatives or visit Parnell's official website to garner further insights on PropofolVet Multidose and how it can elevate their clinical practices. Parnell continues to be at the forefront of innovation in the veterinary pharmaceutical sector, committed to improving the quality of care for companion animals. With this groundbreaking product, Parnell fortifies its position as a leader in veterinary solutions.

About Parnell

Parnell is a fully integrated veterinary pharmaceutical company pioneering the development, manufacturing, and commercialization of innovative animal health solutions. Operating across ten countries, the company is prominent not only in companion animal healthcare but also in production animal pharmaceuticals, augmented by technologies such as its proprietary software platform, mySYNCH™.